Where Does Sonoma Pharmaceuticals Inc. (SNOA) Rank When It Comes To Price-To-Earnings Ratio?


Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) finished Wednesday with an addition of $0.49 to close at $1.69, an upside of 40.83 percent. An average of 19,914,500 shares of common stock have been traded in the last five days. There was a gain of $0.4301 in the past week, and it reached a new high 6 times over the past 12 months. The last 20 days have seen an average of 5,024,645 shares traded, while the 50-day average volume stands at 2,026,794.

SNOA stock has increased by 42.02% in the last month. The company shares reached their 1-month lowest point of $1.0000 on 12/28/22. With the stock rallying to its 52-week high on 01/25/23, shares of the company touched a low of $1.00 and a high of $4.25 in 52 weeks. It has reached a new high 5 times so far this year and achieved 50.89% or $0.5700 in price. In spite of this, the price is down -60.24% from the 52-week high.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Valuation Metrics

Sonoma Pharmaceuticals Inc. (SNOA) stock’s beta is 1.05. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.41, the price-to-book (PB) ratio at 0.75.

Financial Health

The quick ratio of Sonoma Pharmaceuticals Inc. for the recent quarter was 2.70, and the current ratio was 3.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.03 for the recent quarter. Its gross profit as reported stood at $3.99 million compared to revenue of $12.63 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Sonoma Pharmaceuticals Inc.’s return on assets was -33.00%.

Earnings Surprise

For the recent quarter, Sonoma Pharmaceuticals Inc. had $20000.0 in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$1.02 million in the quarter, while revenues were grew 90.2%. Shareholders own equity worth $3.1 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Sonoma Pharmaceuticals Inc. (SNOA) price momentum. RSI 9-day as of the close on 25 January was 75.56%, suggesting the stock is Overbought, with historical volatility in this time frame at 184.62%.

As of today, SNOA’s price is $1.3071 +34.14% or $0.4301 from its 5-day moving average. SNOA is currently trading +46.96% higher than its 20-day SMA and -39.21% lower than its 100-day SMA. However, the stock’s current price level is -12.89% below the SMA50 and -50.15% below the SMA200.

The stochastic %K and %D were 41.74% and 45.83%, respectively, and the average true range (ATR) was 0.2527. With the 14-day stochastic at 38.13% and the average true range at 0.2045, the RSI (14) stands at 66.52%. The stock has reached 0.0861 on the 9-day MACD Oscillator while the 14-day reading was at 0.1308.


Please enter your comment!
Please enter your name here